Information  X 
Enter a valid email address

PSource Struct Debt (PSD)

  Print      Mail a friend

Monday 13 December, 2010

PSource Struct Debt

Portfolio Update

RNS Number : 8391X
PSource Structured Debt Limited
13 December 2010
 



 

 

13 December 2010

PSource Structured Debt Limited ("the Company")

Portfolio Company Update

 

PSource Structured Debt Limited (LSE: PSD, the "Company"), the London listed fund investing in senior secured debt and equity warrants predominantly issued by US based small-cap companies, announces that Biovest International, Inc, the Company's 2nd largest holding, has released updated Phase III data analysis for BiovaxID®, Biovest's personalized vaccine for the treatment of non-Hodgkin's lymphoma.  Their summary of the announcement is set out below.

 

BIOVEST REPORTS A SIGNIFICANT DISCOVERY IN CANCER VACCINES FOR LYMPHOMA: VACCINE ISOTYPE DETERMINES IMPROVEMENT IN DISEASE-FREE SURVIVAL FOLLOWING VACCINE THERAPY

 

TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: "BVTI") today announced at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, an updated Phase III data analysis for BiovaxID®, Biovest's personalized vaccine for the treatment of non-Hodgkin's lymphoma. This analysis suggests that the improved disease-free survival following personalized lymphoma vaccine therapy depends on an integral tumor protein fragment administered as part of each patient's vaccine. In lymphoma, this protein fragment, termed the "isotype", was previously believed to be unimportant to vaccine response. The new analysis further suggests that patients receiving a vaccine with a specific isotype (IgM) experienced a dramatic disease-free survival benefit.

 

The full text of their announcement can be found at http://www.biovest.com/investors.html.

 

 

For further information, please contact:

PSource Capital Limited

Soondra Appavoo

+44 20 7925 3156


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLXLFFBLFBFBD

a d v e r t i s e m e n t